Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04061421 | Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) | PHASE1 | RECRUITING | 94 | — | — | Nov 24, 2021 | Dec 1, 2027 | Apr 21, 2026 | 4 | United States |
Per CTCAE 5.0
| Arm | Type | Description |
|---|---|---|
| ASTX727 + itacitinib | EXPERIMENTAL | ASTX727 and itacitinib will be taken by mouth |
| ASTX727 + ruxolitinib | EXPERIMENTAL | ASTX727 and ruxolitinib will be taken by mouth |
| Name | Type | Description |
|---|---|---|
| ASTX727 | DRUG | Taken by mouth daily during days 1-5 of every 28-day cycle. |
| Itacitinib | DRUG | Taken by mouth daily during each 28-day cycle |
| Ruxolitinib | DRUG | Dosage will be 5,15, or 20mg Taken by mouth BID for 28-day cycle |
Inclusion Criteria: 1. Must be ≥ 18 years of age at the time of signing the Informed Consent Form (ICF); must voluntarily sign an ICF; and must be willing and able to meet all study requirements. 2. Must have morphologically confirmed diagnosis of MDS/MPN, excluding JMML, in accordance with WHO (20...